ReviewFrontiers in aging neuroscience2020
Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia.
Review in Frontiers in aging neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The Diagnostic Value of Exosome-Derived Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment: A Meta-Analysis.Frontiers in aging neuroscience · 2021Pooled it
- Exosomes in Alzheimer's Disease: From Pathological Mechanisms to Biomarker Potential and Therapeutic Applications.Molecular neurobiology · 2026Review
- Extracellular RNAs as Messengers and Early Biomarkers in Neurodegeneration.International journal of molecular sciences · 2025Review
- Neuron-Derived Extracellular Vesicles: Emerging Biomarkers and Functional Mediators in Alzheimer's Disease, With Comparative Insights Into Neurodevelopment and Aging.Developmental neurobiology · 2025Review
- Deficits of Alzheimer's Disease Neuropsychological Architecture Correlate with Specific Exosomal mRNA Expression: Evidence of a Continuum?International journal of molecular sciences · 2025Article
- MicroRNA in neuroexosome as a potential biomarker for HIV-associated neurocognitive disorders.Journal of neurovirology · 2025Article
- A review on gut microbiota and miRNA crosstalk: implications for Alzheimer's disease.GeroScience · 2025Review
- Role of miRNAs in neurovascular injury and repair.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Review
- Exosomal MicroRNAs modulate the cognitive function in fasudil treated APPswe/PSEN1dE9 transgenic (APP/PS1) mice model of Alzheimer's disease.Metabolic brain disease · 2024Article
- Novel C. elegans models of Lewy body disease reveal pathological protein interactions and widespread miRNA dysregulation.Cellular and molecular life sciences : CMLS · 2024Article
- Extracellular Vesicles as Next-Generation Diagnostics and Advanced Therapy Medicinal Products.International journal of molecular sciences · 2024Review
- Research progress on the role of extracellular vesicles in neurodegenerative diseases.Translational neurodegeneration · 2023Review
- Air Pollution: Role of Extracellular Vesicles-Derived Non-Coding RNAs in Environmental Stress Response.Cells · 2023Review
- Extracellular vesicles and Alzheimer's disease in the novel era of Precision Medicine: implications for disease progression, diagnosis and treatment.Experimental neurology · 2022Review
- Review
- Review on the roles of specific cell-derived exosomes in Alzheimer's disease.Frontiers in neuroscience · 2022Review
- Emerging Potential of Exosomal Non-coding RNA in Parkinson's Disease: A Review.Frontiers in aging neuroscience · 2022Review
- Exosomes in Age-Related Cognitive Decline: Mechanistic Insights and Improving Outcomes.Frontiers in aging neuroscience · 2022Review
- microRNAs trip down memory lane.EMBO molecular medicine · 2021Article
- Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia is a syndrome of acquired cognitive impairment that leads to a significant decline in a patient's daily life, ability to learn, and the ability to communicate with others. Dementia occurs in many diseases, including Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal dementia, and Parkinson's disease dementia (PDD). Although the analysis of biomarkers in the cerebrospinal fluid (CSF) and peripheral blood physicochemical analysis can indicate neurological impairment, there are currently no sensitive biomarkers for early clinical diagnosis of dementia or for identifying the cause of dementia. Previous studies have suggested that circulating micro (mi)RNAs may be used as biomarkers for diagnosing neurological disorders. However, miRNAs are susceptible to interference by other components in the peripheral circulation, bringing into question the diagnostic value of circulating miRNAs. Exosomes secreted by most cell types contain proteins, mRNAs, and miRNAs that are closely associated with changes in cellular functions. Exosome miRNAs (ex-miRNAs) are highly stable and resistant to degradation. Therefore, these may serve as useful biomarkers for the early clinical diagnosis of dementia. Here, we review studies of ex-miRNAs that commonly cause clinical dementia and explore whether ex-miRNAs may be used as early diagnostic biomarkers of dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.